Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael J. Kadan is active.

Publication


Featured researches published by Michael J. Kadan.


The FASEB Journal | 2003

Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment.

Kyoichi Takahashi; Yoshitsugu Saishin; Yumiko Saishin; Raquel Lima e Silva; Yuji Oshima; Sachiko Oshima; Michele Melia; Brian Paszkiet; Dennis Zerby; Michael J. Kadan; Gene Liau; Michael Kaleko; Sheila Connelly; Peter A. Campochiaro

Endostatin, a proteolytic fragment of collagen XVIII, is an endogenous inhibitor of tumor angiogenesis that also inhibits choroidal neovascularization. In this study, we assessed the effects of increased intraocular expression of endostatin on vascular endothelial growth factor (VEGF)‐induced changes in the retina. After subretinal injection of a pair of gutless adenoviral vectors (AGV) designed to provide tamoxifen‐inducible expression of endostatin, diffuse endostatin immunoreactivity was induced thoroughout the retina by administration of tamoxifen. Induction of endostatin in double transgenic mice with doxycycline‐induced expression of VEGF in the retina resulted in significant suppression of leakage of intravascular [3H]mannitol into the retina. The ability of endostatin to reduce VEGF‐induced retinal vascular permeability was confirmed by using [3H]mannitol leakage and two other parameters, fluorescein leakage and retinal thickness, after subretinal injection of a bovine immunodeficiency lentiviral vector coding for endostatin (BIV‐vectored endostatin, or BIVendostatin). Subretinal injection of BIVendostatin resulted in more discrete, less intense staining for endostatin in the retina than that seen with the inducible AGV system, which suggested lower levels and allowed visualization of sites where endostatin was concentrated. Endostatin staining outlined retinal blood vessels, which suggested endostatin binding to a component of vessel walls. More prolonged or higher level expression of VEGF in the retina resulted in neovascularization and retinal detachment, both of which were also significantly reduced by BIVendostatin. These data suggest that endostatin may be an endogenous inhibitor of vasopermeability as well as neovascularization. In patients with diabetic retinopathy, endostatin gene transfer may provide a way to decrease the risk of three causes of visual loss: macular edema, neovascularization, and retinal detachment.


Human Gene Therapy | 2003

Optimization of the generation and propagation of gutless adenoviral vectors

Kiran Sakhuja; P. Seshidhar Reddy; Shanthi Ganesh; Floro Cantaniag; Scott Pattison; Paullin Limbach; Dawn B. Kayda; Michael J. Kadan; Michael Kaleko; Sheila Connelly

Adenoviral vectors devoid of all viral coding regions are referred to by many names, including gutless vectors. Gutless vectors display reduced toxicity and immunogenicity, increased duration of transgene expression, and increased coding capacity compared to early generation vectors, which contain the majority of the viral backbone genes. However, the production of gutless vectors at a scale and purity suitable for clinical use has limited the utility of this technology. In this work we describe the optimization of the production of gutless vectors. We constructed an improved helper virus and generated an alternative gutless vector producer cell line, PERC6-Cre. We demonstrated increased gutless vector yields, minimal helper virus contamination, and no replication-competent adenovirus contamination using the optimized system. Furthermore, the PERC6-Cre cells were adapted to serum-free suspension culture and high-titer gutless vector preparations were produced using bioreactor technology, suggesting the feasibility of gutless vector scale-up for clinical use. Finally, we observed that helper virus lacking a packaging signal could be packaged at a low frequency, revealing an inherent limitation to the differential packaging strategy for gutless vector propagation.


Journal of Neurochemistry | 1984

Characterization of 125I-lysergic acid diethylamide binding to serotonin receptors in rat frontal cortex.

Michael J. Kadan; Ann Marie Krohn; Mark J. Evans; Robin L. Waltz; Paul R. Hartig

Abstract: 125I‐Lysergic acid diethylamide (125I‐LSD) is the first 125I‐labeled ligand for serotonin receptor studies. Its binding to rat frontal cortex membranes is saturable, reversible, and stereospecific. Specific binding is linearly dependent on tissue concentration and represents 70–80% of the total binding. Scatchard plots of the binding data are linear with a KD of 1.5 nM, a Bmax of 12.4 fmol/mg wet weight tissue, and a Hill slope of 1.02. The binding kinetics are highly temperature‐dependent. At 37°C the bimolecular association rate constant is 1.28 × 108 min−1M−1 and the dissociation rate constant is 0.087 min−1 (t1/2= 8.0 min). At 0°C < 4% dissociation occurs over 40 min and the association rate is similarly depressed. Inhibition of 125I‐LSD binding by a variety of serotonergic, dopaminergic, and adrenergic ligands reveals a 5‐hydroxytryptamine2 (5‐HT2) serotonergic profile for this binding site. Regional distribution studies of 125I‐LSD binding in rat brain show that areas with the highest levels of binding include the cortex and striatum. Iodinated radioligands can be synthesized with specific activities exceeding 2,000 Ci/mmol, which makes them approximately 75‐fold more sensitive than tritiated radioligands. This high specific activity, coupled with the selectivity of 125I‐LSD for 5‐HT2 sites, makes this ligand a sensitive new probe for 5‐HT2 serotonin receptors.


Human Gene Therapy | 2003

In Vivo Ligand-Inducible Regulation of Gene Expression in a Gutless Adenoviral Vector System

Dennis Zerby; Kiran Sakhuja; P. Seshidhar Reddy; Heather Zimmerman; Dawn B. Kayda; Shanthi Ganesh; Scott Pattison; Terrence Brann; Michael J. Kadan; Michael Kaleko; Sheila Connelly

Transcriptional regulation that is rapid, reversible, and repeatedly inducible would greatly enhance the safety and efficacy of many gene therapy strategies. We developed a chimeric ligand-inducible regulation system based on the human estrogen receptor. This system has two components, the responsive promoter driving expression of the transgene of interest, and the ligand-inducible chimeric transcription factor. The transcription factor is composed of a novel DNA binding domain and a modified estrogen receptor ligand-binding domain. A point mutation in the ligand-binding domain significantly reduces estrogen binding while allowing binding of the estrogen antagonist, tamoxifen. We used a gutless adenoviral vector system and incorporated both components into two separate vectors. A single gutless vector encoding both system components was also generated. The tamoxifen-mediated induciblity of transgene expression of the gutless vector system was compared in vitro and in vivo with the analogous components incorporated into early generation, E1/E2a/E3-deficient adenoviral vectors. In normal mice, both the gutless vector and early generation systems displayed inducibility in the presence of tamoxifen. Importantly, the gutless vector system was inducible to extremely high levels, at least four times over a 2-month period. In contrast, the early generation vector system was inducible only once. Furthermore, the early generation system displayed significant toxicity, as evidenced by extremely high liver enzyme levels, abnormal liver pathology, and rapid loss of vector DNA from the liver, while the gutless vector system displayed minimal toxicity. These data directly demonstrate the improved in vivo function of the tamoxifen-inducible transcriptional regulation system in the context of the gutless adenoviral vectors.


Journal of Virology | 1996

Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy.

Mario Gorziglia; Michael J. Kadan; Soonpin Yei; J Lim; G M Lee; R Luthra; Bruce C. Trapnell


Blood | 1998

Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy

Sheila Connelly; Julie L. Andrews; Angela M. Gallo; Dawn B. Kayda; Jiahua Qian; Leon W. Hoyer; Michael J. Kadan; Mario Gorziglia; Bruce C. Trapnell; Alan McClelland; Michael Kaleko


Archive | 1995

Improved adenoviral vectors and producer cells

Michael J. Kadan; Mario Goziglia; Bruce C. Trapnell


European Journal of Pharmacology | 1983

125I-LSD: A high sensitivity ligand for serotonin receptors

Paul R. Hartig; Michael J. Kadan; M.J. Evans; A.M. Krohn


Synapse | 1991

Correlation of 125I-LSD autoradiographic labeling with serotonin voltage clamp responses in Aplysia neurons

Martyn L. Evans; Michael J. Kadan; Paul R. Hartig; David O. Carpenter


Archive | 2002

Neue östrogenrezeptorligandenbindungsdomänen varianten und neue liganden und pharmazeutische zusammensetzungen

Kathryn Rene Bracken; Los Angeles Joseph E. De; Ying Huang; Michael J. Kadan; Gary Michael Ksander; Dennis Zerby

Collaboration


Dive into the Michael J. Kadan's collaboration.

Top Co-Authors

Avatar

Dennis Zerby

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bruce C. Trapnell

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Paul R. Hartig

Johns Hopkins University

View shared research outputs
Researchain Logo
Decentralizing Knowledge